RU2488591C2 - Аналоги азацитидина и их применение - Google Patents

Аналоги азацитидина и их применение Download PDF

Info

Publication number
RU2488591C2
RU2488591C2 RU2010116274/04A RU2010116274A RU2488591C2 RU 2488591 C2 RU2488591 C2 RU 2488591C2 RU 2010116274/04 A RU2010116274/04 A RU 2010116274/04A RU 2010116274 A RU2010116274 A RU 2010116274A RU 2488591 C2 RU2488591 C2 RU 2488591C2
Authority
RU
Russia
Prior art keywords
aza
cancer
integer
formula
tissue
Prior art date
Application number
RU2010116274/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010116274A (ru
Inventor
Льюис СИЛВЕРМАН
Джеймс Холланд
Марит Лиланд САНДВОЛЬД
Финн МЮРЕН
Оле Хенрик ЭРИКСЕН
Original Assignee
Маунт Синай Скул Оф Медсин
Клавис Фарма Аса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Маунт Синай Скул Оф Медсин, Клавис Фарма Аса filed Critical Маунт Синай Скул Оф Медсин
Publication of RU2010116274A publication Critical patent/RU2010116274A/ru
Application granted granted Critical
Publication of RU2488591C2 publication Critical patent/RU2488591C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
RU2010116274/04A 2007-09-26 2008-09-25 Аналоги азацитидина и их применение RU2488591C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26
US60/975,437 2007-09-26
PCT/US2008/077673 WO2009042767A1 (en) 2007-09-26 2008-09-25 Azacytidine analogues and uses thereof

Publications (2)

Publication Number Publication Date
RU2010116274A RU2010116274A (ru) 2011-11-10
RU2488591C2 true RU2488591C2 (ru) 2013-07-27

Family

ID=40511851

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010116274/04A RU2488591C2 (ru) 2007-09-26 2008-09-25 Аналоги азацитидина и их применение

Country Status (15)

Country Link
US (2) US8158605B2 (enExample)
EP (2) EP2197274A4 (enExample)
JP (2) JP2010540556A (enExample)
KR (2) KR20100102092A (enExample)
CN (2) CN101815437A (enExample)
AU (2) AU2008304380A1 (enExample)
BR (2) BRPI0817269A2 (enExample)
CA (2) CA2700267A1 (enExample)
IL (1) IL204690A0 (enExample)
MX (2) MX2010003002A (enExample)
NZ (2) NZ583923A (enExample)
RU (1) RU2488591C2 (enExample)
UA (2) UA99308C2 (enExample)
WO (2) WO2009042766A1 (enExample)
ZA (1) ZA201001660B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2783535C2 (ru) * 2017-03-20 2022-11-14 Вакцинекс, Инк. Лечение рака с помощью антитела к семафорину 4d в комбинации с эпигенетическим модулирующим агентом
US11572408B2 (en) 2017-03-20 2023-02-07 Vaccinex, Inc. Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
JP2010540556A (ja) * 2007-09-26 2010-12-24 マウント サイナイ スクール オブ メディシン アザシチジン類似体およびその使用
ES2927556T3 (es) 2008-05-15 2022-11-08 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
WO2010014883A2 (en) * 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
AR076418A1 (es) * 2009-04-27 2011-06-08 Reddys Lab Inc Dr Preparacion de decitabina
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
TW201303295A (zh) * 2011-04-15 2013-01-16 克雷維斯製藥公司 偵測血液失調中之人平衡型核苷轉運蛋白１（ｈＥＮＴ１）表現用之系統和方法
JP6162709B2 (ja) 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
MY174308A (en) 2012-02-24 2020-04-06 Signal Pharm Llc Methods for treating non-small cell lung using tor kinase inhibitor combination therapy
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
BR112015026247B1 (pt) * 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
LT3236972T (lt) * 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
CA3007357C (en) 2015-12-03 2023-12-05 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
KR102810546B1 (ko) * 2018-04-19 2025-05-20 써던 리서취 인스티튜트 암의 치료를 위한 4'-티오-뉴클레오타이드 및 -뉴클레오사이드 전구약물
WO2022035852A1 (en) * 2020-08-10 2022-02-17 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
WO1997005154A1 (en) * 1995-07-25 1997-02-13 Norsk Hydro Asa Improved therapeutic agents
RU2116306C1 (ru) * 1990-06-15 1998-07-27 Санкио Компани Лимитед Пиримидин-нуклеозиды, способы их получения, фармацевтическая композиция
RU2000100373A (ru) * 1997-06-03 2002-01-10 Матаеси Девелопмент Ко., Лтд. Природные противоопухолевые или противовирусные вещества и их применение
WO2007035783A2 (en) * 2005-09-19 2007-03-29 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (enExample) 1963-12-22
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4405611A (en) 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4981613A (en) 1986-11-04 1991-01-01 Fuji Photo Film Co., Ltd. Laser light source
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
EP0526646B1 (en) * 1991-02-19 1997-04-23 Fujitsu Limited Semiconductor device having an isolation region enriched in oxygen and a fabrication process thereof
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
HUT70144A (en) 1991-08-14 1995-09-28 Procter & Gamble Pharma Cyclic urethaanes useful as antiarrhythmic and antifibrillatory agents, pharmaceutical compositions containing them, and process for their preparation
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (en) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Novel group 4 transition metal compounds
EP0871710A4 (en) 1995-08-08 2001-03-07 Univ Jefferson RECOMBINANT C-PROTEINASE AND RELATED METHODS, METHODS AND APPLICATIONS
JPH11512440A (ja) 1995-09-15 1999-10-26 スクリプトジェン・ファーマスーティカルズ，インコーポレイテッド 抗菌剤として有用なアリールヒドラゾン誘導体
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
ES2151277T3 (es) 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
PL186888B1 (pl) 1997-01-24 2004-03-31 Conpharma As Pochodne gemcytabiny
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
WO1998055493A1 (fr) * 1997-06-03 1998-12-10 Mori, Takahide Substances naturelles antitumorales ou antivirales et leur utilisation
WO1999026958A1 (en) 1997-11-25 1999-06-03 Protarga, Inc. Nucleoside analog compositions and uses thereof
WO1999041231A1 (en) 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
AU5073100A (en) 1999-06-09 2001-01-02 Bayer Aktiengesellschaft Pyridine carboxamides and their use as plant protection agents
JP4979866B2 (ja) 1999-09-08 2012-07-18 リガンド・ファーマシューティカルズ・インコーポレイテッド 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
PL357418A1 (en) 1999-10-15 2004-07-26 F.Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
MXPA04004712A (es) 2001-11-21 2005-06-20 Heidelberg Pharma Gmbh Derivados fosfolipidos de nucleosidos para uso como farmacos antitumorales.
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
WO2004028454A2 (en) 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
JPWO2004101593A1 (ja) 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
US7244732B2 (en) * 2003-06-20 2007-07-17 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1694642A4 (en) 2003-12-19 2010-10-06 Koronis Pharmaceuticals Inc MUTAGENIC HETEROCYCLES
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
US20080227772A1 (en) 2004-02-04 2008-09-18 Neurosearch A/S Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
EP2407453A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. PGD2 receptor antagonist
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
JP2010540556A (ja) * 2007-09-26 2010-12-24 マウント サイナイ スクール オブ メディシン アザシチジン類似体およびその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
RU2116306C1 (ru) * 1990-06-15 1998-07-27 Санкио Компани Лимитед Пиримидин-нуклеозиды, способы их получения, фармацевтическая композиция
WO1997005154A1 (en) * 1995-07-25 1997-02-13 Norsk Hydro Asa Improved therapeutic agents
RU2000100373A (ru) * 1997-06-03 2002-01-10 Матаеси Девелопмент Ко., Лтд. Природные противоопухолевые или противовирусные вещества и их применение
WO2007035783A2 (en) * 2005-09-19 2007-03-29 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2783535C2 (ru) * 2017-03-20 2022-11-14 Вакцинекс, Инк. Лечение рака с помощью антитела к семафорину 4d в комбинации с эпигенетическим модулирующим агентом
US11572408B2 (en) 2017-03-20 2023-02-07 Vaccinex, Inc. Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

Also Published As

Publication number Publication date
NZ583923A (en) 2012-05-25
CA2700207A1 (en) 2009-04-02
AU2008304380A1 (en) 2009-04-02
MX2010003002A (es) 2010-07-05
KR20100102092A (ko) 2010-09-20
AU2008304381A1 (en) 2009-04-02
JP2010540556A (ja) 2010-12-24
WO2009042766A9 (en) 2009-05-28
CA2700267A1 (en) 2009-04-02
US8399420B2 (en) 2013-03-19
EP2205073A4 (en) 2013-03-06
BRPI0817269A2 (pt) 2014-10-07
JP2010540555A (ja) 2010-12-24
UA99836C2 (en) 2012-10-10
CN101815437A (zh) 2010-08-25
NZ583824A (en) 2012-06-29
BRPI0817234A2 (pt) 2014-09-30
US20090209482A1 (en) 2009-08-20
WO2009042767A1 (en) 2009-04-02
MX2010003261A (es) 2010-08-18
WO2009042766A1 (en) 2009-04-02
CN101877964A (zh) 2010-11-03
UA99308C2 (ru) 2012-08-10
RU2010116154A (ru) 2011-11-10
RU2010116274A (ru) 2011-11-10
US8158605B2 (en) 2012-04-17
EP2205073A1 (en) 2010-07-14
EP2197274A4 (en) 2013-03-06
US20090209477A1 (en) 2009-08-20
EP2197274A1 (en) 2010-06-23
IL204690A0 (en) 2010-11-30
ZA201001660B (en) 2011-05-25
KR20100072230A (ko) 2010-06-30

Similar Documents

Publication Publication Date Title
RU2488591C2 (ru) Аналоги азацитидина и их применение
US12239655B2 (en) Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents
RU2168995C2 (ru) Фармацевтические композиции, соединения, способы получения соединений
US20240238323A1 (en) Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses
JP7558963B2 (ja) 修飾されたマイクロｒｎａ及びがんの処置におけるその使用
WO2017165489A1 (en) Antiviral agents for treating zika and dengue virus infections
US20090192099A1 (en) Prodrugs of heteroaryl compounds
US20140031309A1 (en) Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases
AU2014349328A1 (en) Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment
US7589092B2 (en) Prodrugs of heteroaryl compounds
AU2012312308B2 (en) Romidepsin and 5-azacitidine for use in treating lymphoma
US20190054103A1 (en) Method of treatment of tp53 wild-type tumors with 2',2'-difluoro-5-aza-2'-deoxycytidine or prodrugs thereof
US20060217345A1 (en) Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases
RU2487883C2 (ru) Аналоги азацитидина и их применение
JP6431520B2 (ja) フッ化ピリミジン類縁体及びその使用方法
US9493500B2 (en) Fluorinated pyrimidine analogs and methods of use thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140926